TIDMSNG
RNS Number : 7832Z
Synairgen plc
25 May 2021
Press release
Synairgen plc
('Synairgen' or the 'Company')
Posting of Annual Report and Accounts and Notice of Annual
General Meeting
Southampton, UK - 25 May 2021: Synairgen plc (LSE: SNG), the
respiratory company developing inhaled interferon beta (IFN-beta)
for the treatment of severe viral lung infections, announces that
the Annual Report and Accounts for the year ended 31 December 2020
and Notice of Annual General Meeting were posted to shareholders
today. These documents are available on the Company's website at
www.synairgen.com.
Annual General Meeting
In line with the UK Government's latest guidelines on COVID-19,
Synairgen will host its Annual General Meeting (AGM) as a closed
meeting at 9.00 a.m. on 18 June 2021.
The AGM is an important event for the Company and its
shareholders and Synairgen remains committed to ensuring that
shareholders can exercise their right to vote and ask questions in
advance of the AGM. In light of the ongoing COVID-19 situation and
the restrictions on gatherings implemented by the UK Government,
shareholders will not be able to attend the AGM in person but the
Company is pleased to be able to offer facilities for shareholders
to attend virtually. Synairgen will arrange for a quorum of two
director shareholders to be in place to transact the formal
business of the AGM.
A listen-only webinar facility will be provided to allow
shareholders to attend the AGM and follow proceedings remotely. The
details on how to attend the webinar will be published on the
homepage of the Company's website, www.synairgen.com ,
approximately 72 hours before the date and time of the meeting.
The outcome of the resolutions will be determined by shareholder
vote based on the proxy votes received. Shareholders are therefore
strongly encouraged to vote by proxy on the resolutions contained
in the AGM notice. Given the restrictions on attendance,
shareholders are also strongly encouraged to appoint the "Chairman
of the Meeting" as their proxy rather than another person who will
not be permitted to attend the meeting. To ensure votes are counted
at the AGM, completed proxy forms should either be completed
electronically (using either Link Group's Signal shares online
portal; at www.signalshares.com or if you hold shares in
uncertificated form (i.e. in CREST) by completing a CREST Proxy
Instruction). Alternatively, you may request a hard copy proxy form
from the Registrars, Link Group's general helpline (+44 (0) 371 664
0300), which should be posted to Link Group, 10(th) Floor, Central
Square, 29 Wellington Street, Leeds LS1 4DL and must be received by
9.00 a.m. on 16 June 2021 in order to be valid.
There will be no live Q&A session with the Board at the AGM.
Shareholders can submit questions for the Board in advance of the
AGM by email to AGM2021@synairgen.com, no later than 48 hours ahead
of the AGM taking place, and the Board will endeavour to answer as
many questions as possible immediately following the conclusion of
the routine business of the AGM in the time available. The Board
reserves the right not to answer all the question submitted and
also to aggregate and provide a single answer to multiple questions
in respect of a similar topic.
The results of the AGM will be announced to the London Stock
Exchange and the full results of the proxy voting placed on the
Company's website, in the usual way, as soon as practicable after
the conclusion of the AGM.
The Board would like to thank all shareholders for their
continued support and understanding in these exceptional
circumstances and wish them well during this time.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and
development company founded by University of Southampton Professors
Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product
candidate, SNG001 (inhaled interferon beta) for the treatment of
COVID-19. SNG001 is potentially the first host-targeted
broad-spectrum antiviral treatment delivered directly into the
lungs. The Company is evaluating nebulised SNG001 in its Phase III
clinical programme, which has been deemed an Urgent Public Health
study by the UK's National Institute for Health Research (NIHR).
SNG001 has also been granted Fast Track status from the US Food and
Drug Administration (FDA). In a Phase II trial, COVID-19 patients
with marked/severe breathlessness demonstrated a threefold greater
chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABUGDUIBDDGBU
(END) Dow Jones Newswires
May 25, 2021 11:28 ET (15:28 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024